0 Vote
1 Contributor
186 Views
0 Saved
You might also be interested in
Generally, women having their routine mammogram will receive a letter within one month with normal results. But if the doctor finds something suspicious, they’ll call you back, mostly within just 5 days, to take fresh pictures or other tests. Yes, that call may seem to be scary, but a suspicious fin....
Stage is usually expressed as a number on a scale of 0 through IV — with stage 0 describing non-invasive cancers that remain within their original location and stage IV describing invasive cancers that have spread outside the breast to other parts of the body. Stage 0 Stage I Stage II Stage III ....
Most breast lumps women feel - 8 out of 10 - aren't cancer. It's more common for them to be a cyst (a sac) or a fibroadenoma (an abnormal growth that's not cancer). Some lumps come and go during a woman's menstrual cycle. When you feel a lump in your breast, it's understandable to be concerned. B....
Receive guidance from the first consultation through the entire hospitalization process.
Medical experts assist the patients to find the right doctor and book appointments.
Consult with 5000+ doctors online and get all your health queries answered.
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.